DK0904081T3 - Vandige suspensioner af 9-hydroxyrisperidon-fedtsyreestere - Google Patents

Vandige suspensioner af 9-hydroxyrisperidon-fedtsyreestere

Info

Publication number
DK0904081T3
DK0904081T3 DK97923912T DK97923912T DK0904081T3 DK 0904081 T3 DK0904081 T3 DK 0904081T3 DK 97923912 T DK97923912 T DK 97923912T DK 97923912 T DK97923912 T DK 97923912T DK 0904081 T3 DK0904081 T3 DK 0904081T3
Authority
DK
Denmark
Prior art keywords
fatty acid
acid esters
aqueous suspensions
hydroxyrisperidone fatty
hydroxyrisperidone
Prior art date
Application number
DK97923912T
Other languages
English (en)
Inventor
Marc Karel Jozef Francois
Roger Carolus August Embrechts
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0904081(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0904081T3 publication Critical patent/DK0904081T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
DK97923912T 1996-05-20 1997-05-12 Vandige suspensioner af 9-hydroxyrisperidon-fedtsyreestere DK0904081T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (1)

Publication Number Publication Date
DK0904081T3 true DK0904081T3 (da) 2002-02-25

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97923912T DK0904081T3 (da) 1996-05-20 1997-05-12 Vandige suspensioner af 9-hydroxyrisperidon-fedtsyreestere

Country Status (38)

Country Link
US (1) US6077843A (da)
EP (1) EP0904081B1 (da)
JP (1) JP3274687B2 (da)
KR (1) KR100358373B1 (da)
CN (1) CN1093762C (da)
AR (1) AR007194A1 (da)
AT (1) ATE208619T1 (da)
AU (1) AU715572B2 (da)
BG (1) BG62684B1 (da)
BR (1) BR9706824B8 (da)
CA (1) CA2236691C (da)
CY (2) CY2270B1 (da)
CZ (1) CZ291284B6 (da)
DE (2) DE122011100027I1 (da)
DK (1) DK0904081T3 (da)
EA (1) EA000536B1 (da)
EE (1) EE03594B1 (da)
ES (1) ES2167745T3 (da)
FR (1) FR11C0035I2 (da)
HK (1) HK1017852A1 (da)
HR (1) HRP970276B1 (da)
HU (2) HU224025B1 (da)
ID (1) ID16927A (da)
IL (1) IL124551A (da)
LU (1) LU91842I2 (da)
MX (1) MX9804816A (da)
MY (1) MY126302A (da)
NO (2) NO315931B1 (da)
NZ (1) NZ330369A (da)
PL (1) PL188309B1 (da)
PT (1) PT904081E (da)
SI (1) SI0904081T1 (da)
SK (1) SK284013B6 (da)
TR (1) TR199800923T2 (da)
TW (1) TW487572B (da)
UA (1) UA61898C2 (da)
WO (1) WO1997044039A1 (da)
ZA (1) ZA974331B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU753278B2 (en) * 1998-02-25 2002-10-10 Abbott Laboratories Butorphanol sustained release formulations
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
IL145661A0 (en) 1999-03-31 2002-06-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PL365608A1 (en) * 2000-08-14 2005-01-10 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
PT1539115E (pt) * 2002-07-29 2008-01-14 Alza Corp Métodos e formas de dosagem para libertação controlada de paliperidona
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
DE602004017342D1 (de) 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
JP5306599B2 (ja) * 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
KR101244185B1 (ko) * 2007-04-19 2013-03-25 유씬 리 정신 장애 치료용 신규 화합물, 그의 제조 방법 및 용도
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
EA020697B1 (ru) 2007-12-19 2015-01-30 Янссен Фармацевтика Нв Способ лечения психиатрического пациента путем введения палиперидона пальмитата
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
FI2341905T4 (fi) 2008-09-04 2023-12-04 Amylin Pharmaceuticals Llc Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
BR112012010195A2 (pt) 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
KR101936968B1 (ko) 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8940749B2 (en) 2011-05-31 2015-01-27 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydor-9-hydroxy-2-methyl-4H-pyrido[ 1, 2-A]-pyrimidin-4-one(paliperidone) and paliperidone palmitate
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6728221B2 (ja) 2015-04-07 2020-07-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
PT4025187T (pt) 2020-11-30 2024-02-28 Janssen Pharmaceutica Nv Regimes de administração associados a formulações injetáveis de paliperidona de libertação prolongada
AU2021388842A1 (en) 2020-11-30 2023-07-13 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
DK4025188T3 (da) 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
US20230077039A1 (en) 2021-08-20 2023-03-09 Janssen Pharmaceutica Nv Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ES2172574T5 (es) * 1993-11-19 2012-11-29 Alkermes, Inc. Preparación de micropartículas biodegradables que contienen un agente biológicamente activo
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
NZ307958A (en) * 1995-06-06 1999-02-25 Hoechst Marion Roussel Inc Benzisoxazole and indazole derivatives as long acting antipsychotic agents and particularly in the treatment of schizophrenia
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
HU224025B1 (hu) 2005-05-30
TR199800923T2 (xx) 1999-09-21
JP3274687B2 (ja) 2002-04-15
LU91842I2 (fr) 2011-09-20
MY126302A (en) 2006-09-29
EP0904081A1 (en) 1999-03-31
MX9804816A (es) 1998-10-31
ZA974331B (en) 1998-11-19
FR11C0035I2 (fr) 2013-08-16
AU715572B2 (en) 2000-02-03
KR19990067603A (ko) 1999-08-25
CZ140198A3 (cs) 1999-04-14
TW487572B (en) 2002-05-21
CZ291284B6 (cs) 2003-01-15
EE9800136A (et) 1998-10-15
BR9706824B8 (pt) 2015-02-18
DE69708284T2 (de) 2002-07-25
NO2011015I1 (no) 2011-09-19
DE122011100027I1 (de) 2011-11-17
UA61898C2 (en) 2003-12-15
EA000536B1 (ru) 1999-10-28
US6077843A (en) 2000-06-20
PT904081E (pt) 2002-04-29
EE03594B1 (et) 2002-02-15
BG62684B1 (bg) 2000-05-31
ATE208619T1 (de) 2001-11-15
CY2270B1 (en) 2003-07-04
NO981984D0 (no) 1998-04-30
NO2011015I2 (no) 2013-03-11
PL327995A1 (en) 1999-01-04
EA199800531A1 (ru) 1998-12-24
AR007194A1 (es) 1999-10-13
KR100358373B1 (ko) 2003-02-11
EP0904081B1 (en) 2001-11-14
DE69708284D1 (de) 2001-12-20
HRP970276A2 (en) 1998-04-30
NO315931B1 (no) 2003-11-17
CN1093762C (zh) 2002-11-06
HUS1100013I1 (hu) 2017-03-28
SK284013B6 (sk) 2004-08-03
CY2011011I1 (el) 2016-12-14
CN1206347A (zh) 1999-01-27
BG102443A (en) 1999-06-30
ID16927A (id) 1997-11-20
WO1997044039A1 (en) 1997-11-27
PL188309B1 (pl) 2005-01-31
SK62098A3 (en) 2000-04-10
ES2167745T3 (es) 2002-05-16
FR11C0035I1 (da) 2011-07-10
CY2011011I2 (el) 2016-12-14
BR9706824A (pt) 1999-03-23
IL124551A0 (en) 1998-12-06
HUP9901319A3 (en) 1999-11-29
NZ330369A (en) 2000-04-28
CA2236691A1 (en) 1997-11-27
SI0904081T1 (en) 2002-04-30
IL124551A (en) 2001-08-26
NO981984L (no) 1998-11-19
CA2236691C (en) 2007-01-02
AU2955997A (en) 1997-12-09
JP2000513718A (ja) 2000-10-17
HRP970276B1 (en) 2002-04-30
HK1017852A1 (en) 1999-12-03
HUP9901319A2 (hu) 1999-08-30

Similar Documents

Publication Publication Date Title
DK0904081T3 (da) Vandige suspensioner af 9-hydroxyrisperidon-fedtsyreestere
DK1033987T3 (da) Vandige suspensioner af submikron 9-hydroxyrisperidon-fedtsyreestere
FI950910A0 (fi) Rasvahappojohdannaiset
DE69620798T2 (de) Sulfonsäureester von duftstoffen
DE59913680D1 (de) Fettsäurepartialester von Polyolen
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
DE59803990D1 (de) Verwendung von fettsäurepolyglycolestersulfaten
DE69515479D1 (de) Fettsäureester von verätherten polyalkoholen
DK142193D0 (da) Anvendelse af fedtsyreestere
DE69809692T2 (de) Herstellung von Carbonsäureestern
DK0931051T3 (da) Fremgangsmåde til fremstilling af fedtsyreestere